Lumen Bioscience's investigational oral biologic LMN-201 achieved a 100% clinical cure rate in all 21 patients of the sentinel cohort in the RePreve trial for C. difficile infection, significantly outperforming standard treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.